ReviewJournal of cancer research and clinical oncology2018
Role of natural killer cells in lung cancer.
Review in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 77 citations in OpenAlex.
- Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia - a randomized controlled trial.BMC anesthesiology · 2019Trial
- A 7-gene expression signature predicts immune microenvironment remodeling and neoadjuvant chemo-immunotherapy response in lung squamous cell carcinoma.Frontiers in immunology · 2026Article
- Phenotypes, mechanisms, and therapeutic strategies of natural killer cell immunosenescence.Immunity & ageing : I & A · 2025Review
- A Rare Case of Long-Term Survival in Stage IIIB Lung Adenocarcinoma: an 9-Year Follow-Up.Biological procedures online · 2025Article
- Sonodynamic biomimetic-nanomedicine fight cancers.Journal of nanobiotechnology · 2025Review
- The immune microenvironment of lung adenocarcinoma featured with ground-glass nodules.Thoracic cancer · 2024Review
- A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer.Frontiers in immunology · 2024Review
- T cell senescence: a new perspective on immunotherapy in lung cancer.Frontiers in immunology · 2024Review
- Anchoring Filament Protein Ladinin-1 is an Immunosuppressive Microenvironment and Cold Tumor Correlated Prognosticator in Lung Adenocarcinoma.Biochemical genetics · 2023Article
- Higher cytotoxic activities of CD8BMC immunology · 2023Article
- Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.Thoracic cancer · 2023Article
- MRPL12 Acts as A Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression of Lung Adenocarcinoma.International journal of molecular sciences · 2023Article
- Hsa-miR-301a-3p inhibited the killing effect of natural killer cells on non-small cell lung cancer cells by regulating RUNX3.Cancer biomarkers : section A of Disease markers · 2023Article
- Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review.Frontiers in oncology · 2023Review
- Role of non-coding RNA in immune microenvironment and anticancer therapy of gastric cancer.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Optimal regulation of tumour-associated neutrophils in cancer progression.Royal Society open science · 2022Article
- Identification of a prognostic index system and tumor immune infiltration characterization for lung adenocarcinoma based on mRNA molecular of pyroptosis.Frontiers in medicine · 2022Article
- Perioperative Inflammatory Response and Cancer Recurrence in Lung Cancer Surgery: A Narrative Review.Frontiers in surgery · 2022Review
- Identification of a prognostic immune-related signature for small cell lung cancer.Cancer medicine · 2021Article
- Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOne of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival.
methodsThe relevant literature from PubMed and Medline databases is reviewed in this article.
resultsThe cytolytic potential of NK cells are reduced in lung cancer and increasing evidence suggests that improving NK cell functioning may induce tumor regression. Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival.
conclusionsThe NK cell targeting strategy has not yet been approved for lung cancer treatment. More clinical studies focusing on the role of NK cells in lung cancer pathogenesis are warranted to develop novel NK cell-based therapeutic approaches for the treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.